Investors

Corporate Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Corporate Investor Presentation

Rigel Corporate Investor Presentation

Date	Title
06/13/19	Rigel to Present Two Posters Highlighting Fostamatinib at the 24ᵗʰ Congress of the European Hematology Association (EHA) SOUTH SAN FRANCISCO , June 13, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present data on fostamatinib disodium hexahydrate (fostamatinib) in two posters at the 24 th Congress of the European Hematology Association (EHA) in Amsterdam, The
05/31/19	Rigel to Present at Jefferies 2019 Healthcare Conference SOUTH SAN FRANCISCO, Calif. , May 31, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2019 Healthcare Conference in New York City on Wednesday,
05/16/19	Rigel Enrolls First Patient in Phase 3 Clinical Trial of Fostamatinib Disodium Hexahydrate in Warm Autoimmune Hemolytic Anemia Announces resignation of Chief Medical Officer effective August 31, 2019 SOUTH SAN FRANCISCO, Calif. , May 16, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of fostamatinib disodium

Stock Quote

(Common Stock)
Exchange	(US Dollar)
Price
Change (%)
Volume
Data as of

E-mail Alerts

Click here to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site

Investors

Investors

Corporate Profile

Corporate Investor Presentation

Stock Quote

Stock Chart

E-mail Alerts